RxDoctor Payments Data

Bradford Ebright, MD

Family Medicine · Baltimore, MDNPI 1053316158

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 209 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$559
  • Novo Nordisk$521
  • AstraZeneca$503
  • AbbVie$447
  • Boehringer Ingelheim$329
  • Pfizer$276
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,750100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,758 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$365,507
Medicare patients
692
Services billed
4,282

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$120,483
JardianceEmpagliflozin53$77,340
TrulicityDulaglutide28$52,414
FarxigaDapagliflozin Propanediol34$37,974
RybelsusSemaglutide13$33,084
OzempicSemaglutide15$28,237
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,641
Atorvastatin Calcium444$5,402
Rosuvastatin Calcium232$4,160
Oxycodone Hcl91$3,791
Testosterone14$3,517
SpsSodium Polystyrene Sulfon/Sorb16$3,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,794
Metoprolol Succinate172$2,758
Amlodipine Besylate317$2,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$276$120,48384 claims
Boehringer IngelheimJardiance$329$77,34053 claims
Novo NordiskRybelsus, Ozempic$521$61,32028 claims
Lilly USA, LLCTrulicity$559$52,41428 claims
AstraZenecaFarxiga$503$37,97434 claims
AbbVieSynthroid$447$1,89457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →